Methylenetetrahydrofolate Reductase Polymorphism, Type II Diabetes Mellitus, Coronary Artery Disease, and Essential Hypertension in the Czech Population

Beneš, Petr; Kaňková, Kateřina; Mužı́k, Jan; Groch, Ladislav; Benedı́k, Jaroslav; Elbl, Lubomı́r; IzakovičováHollá, Lydie; Vašků, Anna; Znojil, Vladimı́r; Vácha, Jiří

doi:10.1006/mgme.2001.3188

Cited by 45 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study tested the MTHFR C677T variant for association with EH in a Caucasian casecontrol panel from Australia. The results of this work were consistent with the trends reported by Benes et al (15), showing that the prevalence of the T allele and its composite genotypes (CT/TT and TT) were increased in the HT group compared to NT controls. Interestingly, the MTHFR C677T considered under a dominant state (CT/TT) appeared to be significantly associated with EH after adjusting for the confounding effect of BMI.…”

Section: Discussionsupporting

confidence: 93%

“…These data also indicated an increased prevalence of the dominant genotype group (CT/TT) compared to controls. Neither of these observed differences was significant, although these researchers did not report the BMI-adjusted effect of MTHFR C677T on EH in this study (15).…”

Section: Discussioncontrasting

confidence: 69%

“…A Spanish case-control study of similar size to our present study also detected an association between MTHFR TT genotype but in males with a greater risk ( 2.3) (12). In contrast, a recent study of CVD in an unrelated group from the Czech Republic examined the MTHFR C677T in 193 patients diagnosed with EH only (15). The frequency of the T allele was shown to be over-represented in the Czech group affected with EH compared to the healthy control group in this Czech study (38% vs. 33%).…”

Section: Discussionsupporting

confidence: 69%

See 2 more Smart Citations

The Methylentetrahydrofolate Reductase Gene Variant (C677T) as a Risk Factor for Essential Hypertension in Caucasians

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussioncontrasting

confidence: 69%

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

The Methylentetrahydrofolate Reductase Gene Variant (C677T) as a Risk Factor for Essential Hypertension in Caucasians

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The 677C/T polymorphism, specifically, has also been reported to be associated with coronary artery disease [59,60], diabetes [61], diabetic nephropathy [62], carotid stenosis and hypertension [63,64].…”

Section: Discussionmentioning

confidence: 99%

Association of FTO , LEPR and MTHFR Gene Polymorphisms with Metabolic Syndrome in Schizophrenia Patients Receiving Antipsychotics

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Although there is strong evidence linking this polymorphism with hypertension, a number of observational studies have reported conflicting or inconclusive results. Many of the studies that failed to detect significant associations used small sample sizes or suffered possible selection bias (93,(95)(96)(97)(98)(99) . Some studies have reported a gender specific association; one large population study in >3000 Japanese individuals reported that the MTHFR 677C T polymorphism was associated with a 42 % increased risk of hypertension in women but not in men (96) .…”

Section: Novel Role Of Mthfr Genotype and Blood Pressurementioning

confidence: 99%

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

et al. 2016

View full text Add to dashboard Cite

Clinical deficiency of the B-vitamin riboflavin (vitamin B 2 ) is largely confined to developing countries; however accumulating evidence indicates that suboptimal riboflavin status is a widespread problem across the developed world. Few international data are available on riboflavin status as measured by the functional biomarker, erythrocyte glutathione reductase activation coefficient, considered to be the gold standard index. One important role of riboflavin in the form of flavin dinucleotide is as a co-factor for the folate-metabolising enzyme methylenetetrahydrofolate reductase (MTHFR). Homozygosity for the common C677T polymorphism in MTHFR, affecting over 10 % of the UK and Irish populations and up to 32 % of other populations worldwide, has been associated with an increased risk of CVD, and more recently with hypertension. This review will explore available studies reporting riboflavin status worldwide, the interaction of riboflavin with the MTHFR C677T polymorphism and the potential role of riboflavin in personalised nutrition. Evidence is accumulating for a novel role of riboflavin as an important modulator of blood pressure (BP) specifically in individuals with the MTHFR 677TT genotype, with results from a number of recent randomised controlled trials demonstrating that riboflavin supplementation can significantly reduce systolic BP by 5-13 mmHg in these genetically at risk adults. Studies are however required to investigate the BP-lowering effect of riboflavin in different populations and in response to doses higher than 1·6 mg/d. Furthermore, work focusing on the translation of this research to health professionals and patients is also required.Riboflavin: Methylenetetrahydrofolate reductase: MTHFR C677T: Blood pressure:Personalised nutrition Riboflavin (vitamin B 2 ) is a water-soluble B-vitamin defined chemically as 7,8-dimethyl-10-1′-D-ribityl isoalloxazine. It acts as a precursor for FMN and FAD (1) . Clinical riboflavin deficiency is not generally considered to be a problem in the developed world but in recent years evidence has shown that sub-optimal status may be more widespread than generally perceived based on studies reporting the functional biomarker, erythrocyte glutathione reductase activation coefficient (EGRac) generally considered as the gold standard index of status. Few international data are however available based on EGRac and reports on riboflavin status are more commonly based solely on dietary intake data. Although riboflavin is required for numerous metabolic reactions its role (in the form of FAD) as a cofactor for the folatemetabolising enzyme, methylenetetrahydrofolate reductase (MTHFR) has recently received particular attention. Homozygosity (MTHFR 677TT genotype) for a common polymorphism in MTHFR, affecting over 10 % of the UK and Irish populations and up to 32 % of other populations worldwide (2) , has been associated with an increased risk of CVD (3) and more recently with hypertension (4) . Emerging evidence from intervention trials supports a novel role for riboflav...

show abstract

Methylenetetrahydrofolate Reductase Polymorphism, Type II Diabetes Mellitus, Coronary Artery Disease, and Essential Hypertension in the Czech Population

Cited by 45 publications

References 30 publications

The Methylentetrahydrofolate Reductase Gene Variant (C677T) as a Risk Factor for Essential Hypertension in Caucasians

The Methylentetrahydrofolate Reductase Gene Variant (C677T) as a Risk Factor for Essential Hypertension in Caucasians

Association of FTO , LEPR and MTHFR Gene Polymorphisms with Metabolic Syndrome in Schizophrenia Patients Receiving Antipsychotics

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

Contact Info

Product

Resources

About